Dabigatran etexilate

Dabigatran etexilate Reactions 1680, p110 - 2 Dec 2017 of patients. However, this treatment is associated with the risk of bleeding." Giustozzi M, et al. Reversal of dabigatran-associated bleeding using idarucizumab: Rectal and pelvic bleeding: 2 case reports review of the current evidence. Journal of Thrombosis and Thrombolysis 44: 527-535, No. 4, Nov 2017. Available from: URL: http://doi.org/10.1007/ In a case series, an 80-year-old man developed rectal s11239-017-1555-4 - Italy 803284048 bleeding and an 85-year-old woman developed pelvic bleeding following the therapy with dabigatran etexilate [dabigatran]. Case 1: The 80-year-old man was admitted with abdominal pain, severe diarrhoea and at least 4 episodes of acute rectal bleeding over the last 24 hours. He had been receiving therapy with oral dabigatran etexilate 110mg twice daily as an anticoagulant for non-valvular atrial fibrillation since the past two years. His latest administration of dabigatran etexilate was 12 hours prior to the presentation. He had a history of anaemia. At presentation, his laboratory tests revealed the following: BP 80/50mm Hg, heart rate 89 beats/minute and oxygen saturation 95% in room air. Laboratory tests reported worsened anaemia, deteriorated renal failure (stage 3b as per Kidney Disease Outcomes Quality Initiative guidelines) and a prolongation of clotting times. It was consequently revealed that his life threatening bleeding was associated with the administration of dabigatran etexilate. The man then received red blood cells and fluids. Thereafter, his BP and haemodynamic findings stabilised. The next morning, repeated episodes of rectorrhagia occurred and the haemodynamic state rapidly worsened. Despite blood transfusions, his haemoglobin level decreased and a prolongation of clotting times continued. His therapy with dabigatran etexilate was discontinued. He then received idarucizumab as an antidote and additional units of red blood cells. Subsequently, the active prothrombin time and prothrombin time normalised. His haeamoglobin remained stable with no further episodes of rectal bleeding or haeamoglobin reductions. No further thromboembolic complications manifested. The man’s dabigatran etexilate therapy was re-started within a month after the discharge. Case 2: The 85-year-old woman was admitted due to worsening asthenia and syncope. She had been receiving anticoagulation therapy with oral dabigatran etexilate 110mg twice daily for non-valvular atrial fibrillation from 2014. Her latest administration was 2 hours before the admission. On admission, she was drowsy (Glasgow Coma Scale 10), haemodynamically unstable and had signs of systemic hypoperfusion. Her haemoglobin was 6.4 g/dL and coagulation tests showed prolonged values. Creatinine clearance results were performed using the Cockroft-Gault and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation formula and were found to be 16.4 and 19.4 mL/min, respectively. Blood gas analysis demonstrated the manifestation of metabolic acidosis. She eventually developed renal failure. A complete bedside ultrasonography showed a complex mass in the pelvis. The woman received tranexamic acid, fresh-frozen plasma and sodium chloride [saline]. A total- body CT scan with contrast medium revealed a 12cm pelvic haematoma with bladder displacement, leading to a suspicion of active bleeding. It was revealed that her life threatening bleeding was associated with the administration of dabigatran etexilate. Her therapy with dabigatran etexilate was discontinued. She received treatment with idarucizumab as an antidote. Subsequently, the bleeding manifestation stabilised. No side effects were recorded during the infusion and no thromboembolic complications were referred or observed during hospital stay. She was transfused with 3 units of red blood cells and her clinical condition improved during the hospital stay. The woman’s dabigatran etexilate therapy was re-initiated within a month after the discharge. Author comment: "Here, we report on the use of idarucizumab in two patients who experienced life- threatening bleeding while on treatment with [dabigatran etexilate]". "Oral anticoagulant treatment reduces the incidence of stroke or systemic embolism by about 60% in patients with [atrial fibrillation], and the incidence of recurrence of venous thromboembolism (VTE) in about 90% 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Dabigatran etexilate

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/dabigatran-etexilate-0Y1THliG2D
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39041-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p110 - 2 Dec 2017 of patients. However, this treatment is associated with the risk of bleeding." Giustozzi M, et al. Reversal of dabigatran-associated bleeding using idarucizumab: Rectal and pelvic bleeding: 2 case reports review of the current evidence. Journal of Thrombosis and Thrombolysis 44: 527-535, No. 4, Nov 2017. Available from: URL: http://doi.org/10.1007/ In a case series, an 80-year-old man developed rectal s11239-017-1555-4 - Italy 803284048 bleeding and an 85-year-old woman developed pelvic bleeding following the therapy with dabigatran etexilate [dabigatran]. Case 1: The 80-year-old man was admitted with abdominal pain, severe diarrhoea and at least 4 episodes of acute rectal bleeding over the last 24 hours. He had been receiving therapy with oral dabigatran etexilate 110mg twice daily as an anticoagulant for non-valvular atrial fibrillation since the past two years. His latest administration of dabigatran etexilate was 12 hours prior to the presentation. He had a history of anaemia. At presentation, his laboratory tests revealed the following: BP 80/50mm Hg, heart rate 89 beats/minute and oxygen saturation 95% in room air. Laboratory tests reported worsened anaemia, deteriorated renal failure (stage 3b as per Kidney Disease Outcomes Quality Initiative guidelines) and a prolongation of clotting times. It was consequently revealed that his life threatening bleeding was associated with the administration of dabigatran etexilate. The man then received red blood cells and fluids. Thereafter, his BP and haemodynamic findings stabilised. The next morning, repeated episodes of rectorrhagia occurred and the haemodynamic state rapidly worsened. Despite blood transfusions, his haemoglobin level decreased and a prolongation of clotting times continued. His therapy with dabigatran etexilate was discontinued. He then received idarucizumab as an antidote and additional units of red blood cells. Subsequently, the active prothrombin time and prothrombin time normalised. His haeamoglobin remained stable with no further episodes of rectal bleeding or haeamoglobin reductions. No further thromboembolic complications manifested. The man’s dabigatran etexilate therapy was re-started within a month after the discharge. Case 2: The 85-year-old woman was admitted due to worsening asthenia and syncope. She had been receiving anticoagulation therapy with oral dabigatran etexilate 110mg twice daily for non-valvular atrial fibrillation from 2014. Her latest administration was 2 hours before the admission. On admission, she was drowsy (Glasgow Coma Scale 10), haemodynamically unstable and had signs of systemic hypoperfusion. Her haemoglobin was 6.4 g/dL and coagulation tests showed prolonged values. Creatinine clearance results were performed using the Cockroft-Gault and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation formula and were found to be 16.4 and 19.4 mL/min, respectively. Blood gas analysis demonstrated the manifestation of metabolic acidosis. She eventually developed renal failure. A complete bedside ultrasonography showed a complex mass in the pelvis. The woman received tranexamic acid, fresh-frozen plasma and sodium chloride [saline]. A total- body CT scan with contrast medium revealed a 12cm pelvic haematoma with bladder displacement, leading to a suspicion of active bleeding. It was revealed that her life threatening bleeding was associated with the administration of dabigatran etexilate. Her therapy with dabigatran etexilate was discontinued. She received treatment with idarucizumab as an antidote. Subsequently, the bleeding manifestation stabilised. No side effects were recorded during the infusion and no thromboembolic complications were referred or observed during hospital stay. She was transfused with 3 units of red blood cells and her clinical condition improved during the hospital stay. The woman’s dabigatran etexilate therapy was re-initiated within a month after the discharge. Author comment: "Here, we report on the use of idarucizumab in two patients who experienced life- threatening bleeding while on treatment with [dabigatran etexilate]". "Oral anticoagulant treatment reduces the incidence of stroke or systemic embolism by about 60% in patients with [atrial fibrillation], and the incidence of recurrence of venous thromboembolism (VTE) in about 90% 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off